Clinicopathological Features of Adult Lymphoblastic Lymphoma Patients: Data from Turkiye

Introduction Lymphoblastic lymphoma (LBL) is a highly malignant tumor composed of immature lymphocytes derived from B or T cells. LBL is usually distinguished from ALL by the presence of less than 25% of bone marrow-invading blasts. Our study examined the data of LBL patients diagnosed and treated at centers within our country. Material method Thirty-eight patients from seven distinct tertiary adult hematology clinics were chosen for this investigation. Individuals aged 18 and older with a pathologically confirmed diagnosis of LBL, who had radiological assessments for clinical staging and received a minimum of one chemotherapy regimen, were included in the study. Results Overall survival (OS) for all patients was 23 months, 21 months for patients with T-LBL, and 56 months for individuals with B-LBL. Despite a significant difference in overall survival (OS) between patients diagnosed with T-LBL and those diagnosed with B-LBL, no significant difference in OS was found between the two groups (p > 0.05). The median progression-free survival (PFS) of the patients was determined as 6 months. Discussion The data from our study indicate that elevated LDH levels, central nervous system involvement, involvement in three or more regions, cervical lymph node involvement, achieving remission after the initial treatment, and male gender (with no significant difference observed in the T-LBL subgroup) adversely affect prognosis.